Law360, New York (November 14, 2003, 12:00 AM EST) -- Takeda Abbott Pharmaceuticals Products, Takeda Chemical Industries and Wako Pure Chemical Industries sued Atrix Laboratories and its licensee, Sanofi-Synthelabo, alleging that Atrix's Eligard delivery system infringes on a patent for a biodegradable high molecular polymer excipient held by Takeda Chemical Industries.
The Eligard products use Atrix's proprietary Atrigel sustained-release drug delivery technology, Atrix said. The liquid Eligard products are injected subcutaneously with a small gauge needle forming a solid implant in the body that slowly releases leuprolide as the implant is bioabsorbed.
Atrix chief executive David...
Takeda Abbott Pharmaceuticals Sues Atrix
To view the full article, register now.
Try Law360 FREE for seven days
Already a subscriber? Click here to login
